K. Klinghammer

发表

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

W. Fiedler, M. Kebenko, I. Matos, 2022, ESMO open.

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

G. Folprecht, A. Dietz, S. Rottey, 2021, ESMO open.

Support of a molecular tumour board by an evidence-based decision management system for precision oncology.

M. Yaspo, F. Klauschen, D. Lenze, 2020, European journal of cancer.

Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies

I. Tinhofer, D. Braunholz, K. Klinghammer, 2020, Cancers of the Head & Neck.

Targeted Therapy of Head and Neck Cancer

D. Rieke, U. Keilholz, K. Klinghammer, 2016, Oncology Research and Treatment.

Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

V. Budach, I. Tinhofer, U. Keilholz, 2009, Clinical Cancer Research.

Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment

W. Weichert, A. Stenzinger, V. Budach, 2011, Clinical Cancer Research.

Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence.

W. Weichert, A. Stenzinger, V. Budach, 2015, European journal of cancer.

PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab‐docetaxel

U. Keilholz, K. Klinghammer, M. Knödler, 2015, Head & neck.

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.

N. Utku, U. Keilholz, A. Schmittel, 2017, European journal of cancer.

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

I. Tinhofer, J. Hoffmann, J. Raguse, 2020, Oncotarget.

Reactive oxygen species in cancer stem cells of head and neck squamous cancer.

H. Sudhoff, A. Kaufmann, A. Albers, 2018, Seminars in cancer biology.

Developmental delay in hypoxia-induced HO-1 expression predisposes to gut injury

C. Bührer, K. Klinghammer, B. Rüstow, 2012, Journal of perinatal medicine.

Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers

P. Jank, I. Tinhofer, A. Hauser, 2022, Cancers.

An Optimized Research Process for Real-time Drug Response Analysis

H. Plattner, M. Schapranow, K. Klinghammer, 2014 .

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group

J. Machiels, P. Bossi, C. Simon, 2022, Frontiers in Oncology.

Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial

T. Gauler, R. Fietkau, P. Martus, 2021, Oncology Research and Treatment.

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).

Harry W. Lindeman, T. Gauler, A. Dietz, 2019, European journal of cancer.

Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study.

M. Yaspo, F. Klauschen, F. Konietschke, 2022, European journal of cancer.

A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

I. Fichtner, J. Hoffmann, T. Plath, 2015, International journal of cancer.

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix

F. Klauschen, I. Tinhofer, T. Seiwert, 2016, Oncotarget.

Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC

S. Fröhling, B. Obermayer, W. Weichert, 2020, International journal of cancer.

Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC

S. Fröhling, B. Obermayer, W. Weichert, 2019, bioRxiv.

Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts

H. Sudhoff, A. Deleo, A. Kaufmann, 2021, Cells.

Choosing wisely - Preclinical test models in the era of precision medicine.

J. Hoffmann, W. Walther, K. Klinghammer, 2017, Cancer treatment reviews.

Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer

U. Leser, I. Tinhofer, I. Fichtner, 2017, International journal of cancer.

Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets

T. Clauditz, T. Lange, U. Schumacher, 2021, International journal of cancer.

pN status predicts outcomes in surgically treated pT1–pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study

B. Wollenberg, A. Kaufmann, A. Albers, 2018, Laryngo-Rhino-Otologie.

Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients

I. Tinhofer, H. Olze, M. Beck, 2022, Cancers.

Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma

W. Weichert, J. Budczies, S. Combs, 2020, British Journal of Cancer.

155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT

A. Atasoy, Ö. Türeci, R. Greil, 2022, Immuno-Oncology and Technology.

A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development.

I. Tinhofer, U. Keilholz, M. Schäfer-Korting, 2020, Biomaterials.

A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers

M. Hayman, J. Hoffmann, K. Klinghammer, 2018, International journal of cancer.

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma

D. Beule, D. Rieke, E. Blanc, 2023, Frontiers in Oncology.

Animal models for personalized treatment options.

I. Fichtner, J. Hoffmann, B. Jandrig, 2017, International journal of clinical pharmacology and therapeutics.

In-memory technology enables interactive drug response analysis

Hasso Plattner, Matthieu-P. Schapranow, Konrad Klinghammer, 2014, 2014 IEEE 16th International Conference on e-Health Networking, Applications and Services (Healthcom).

Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.

I. Tinhofer, K. Klinghammer, M. Boxberg, 2024, Oral oncology.

Employing head and neck cancer patient derived xenografts to inform clinical trial design: Results from combining regorafenib with everolimus.

I. Fichtner, D. Zopf, J. Hoffmann, 2015 .